Pneumococcal vaccination and pneumonia: Even a low level of clinical effectiveness is highly cost-effective

Clinical Infectious Diseases

Volumn 33, Issue 12, 2001, Pages 2078-2079

  Ament, A ^a   Fedson, D S ^b   Christie, P ^c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b SANOFI PASTEUR   (France)

^c Scottish Centre for Infection and Environmental Health   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

AGING; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HIGH RISK POPULATION; HUMAN; IMMUNE DEFICIENCY; INFECTION PREVENTION; INFLUENZA VACCINATION; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA;

COST-BENEFIT ANALYSIS; HUMANS; PNEUMOCOCCAL VACCINES; PNEUMONIA, BACTERIAL; VACCINATION;

EID: 0035893180     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/324356     Document Type: Article

References (5)

1. The clinical effectiveness of pneumococcal vaccination: A brief review
2. Pneumococcal vaccination in the United States and 20 other developed countries, 1981-1996
3. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people
4. The cost-effectiveness of pneumococcal vaccination for older people: A study in 5 western European countries
5. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease